CNSX:AGN

Stock Analysis Report

Executive Summary

Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.

Share Price & News

How has Algernon Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AGN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-7.7%

AGN

-14.0%

CA Pharmaceuticals

0.6%

CA Market


1 Year Return

-77.8%

AGN

-49.9%

CA Pharmaceuticals

7.1%

CA Market

Return vs Industry: AGN underperformed the Canadian Pharmaceuticals industry which returned -49.9% over the past year.

Return vs Market: AGN underperformed the Canadian Market which returned 7.1% over the past year.


Shareholder returns

AGNIndustryMarket
7 Day-7.7%-14.0%0.6%
30 Day-40.0%-15.7%3.2%
90 Day-52.0%-38.1%4.3%
1 Year-77.8%-77.8%-49.9%-49.9%10.7%7.1%
3 Year-85.4%-85.4%2.8%2.1%18.4%7.8%
5 Yearn/a191.6%191.6%26.8%8.2%

Price Volatility Vs. Market

How volatile is Algernon Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Algernon Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AGN is good value based on its PB Ratio (0.5x) compared to the CA Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Algernon Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

74.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Algernon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Algernon Pharmaceuticals performed over the past 5 years?

38.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AGN has high quality earnings.

Growing Profit Margin: Insufficient data to determine if AGN's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: AGN is unprofitable, but has reduced losses over the past 5 years at a rate of 38.1% per year.

Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.4%).


Return on Equity

High ROE: AGN has a negative Return on Equity (-30.79%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Algernon Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: AGN's short term assets (CA$590.0K) exceeds its short term liabilities (CA$233.1K)

Long Term Liabilities: AGN has no long term liabilities


Debt to Equity History and Analysis

Debt Level: AGN is debt free.

Reducing Debt: AGN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: AGN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AGN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AGN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AGN has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.7% each year.


Next Steps

Dividend

What is Algernon Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.7%industryaverage2.7%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AGN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of Algernon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

2.1yrs

Average management tenure


CEO

Chris Moreau 0

1.7yrs

Tenure

CA$108,000

Compensation

Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer at Algernon Pharmaceuticals Inc. (f.k.a. Breathtec Biomedical Inc.) since March 1, 2018. Mr. Moreau has been the Chief Execu ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD81.65K) is below average for companies of similar size in the Canadian market ($USD136.08K).

Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.


Management Age and Tenure

2.1yrs

Average Tenure

Experienced Management: AGN's management team is considered experienced (2.1 years average tenure).


Board Age and Tenure

4.1yrs

Average Tenure

51yo

Average Age

Experienced Board: AGN's board of directors are considered experienced (4.1 years average tenure).


Insider Trading

Insider Buying: AGN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$16,50030 Sep 19
Kulwant Malhi
EntityIndividual
Shares150,000
Max PriceCA$0.11
BuyCA$8,84523 Jul 19
Kulwant Malhi
EntityIndividual
Shares29,000
Max PriceCA$0.30
BuyCA$7,20005 Jun 19
Christopher Moreau
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares780,000
Max PriceCA$0.24
SellCA$27,69309 Apr 19
Michael S. Sadhra
EntityIndividual
Role
Member of the Board of Directors
CFO & Director
Shares117,343
Max PriceCA$0.24

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.8%.


Management Team

  • Chris Moreau

    Chief Executive Officer

    • Tenure: 1.7yrs
    • Compensation: CA$108.00k
  • Michael S. Sadhra (50yo)

    CFO & Director

    • Tenure: 4.1yrs
    • Compensation: CA$48.00k
  • Alfred Wong

    Vice President of Corporate Development & Communications

    • Tenure: 2.5yrs
    • Compensation: CA$26.00k
  • Mark Williams

    Chief Science Officer

    • Tenure: 1.1yrs

Board Members

  • Michael S. Sadhra (50yo)

    CFO & Director

    • Tenure: 4.1yrs
    • Compensation: CA$48.00k
  • Arun Sanyal

    Member of Medical & Scientific Advisory Board

    • Tenure: 0.7yrs
  • Raj Attariwala (51yo)

    Independent Director

    • Tenure: 4.1yrs
  • David Levine (52yo)

    Independent Director

    • Tenure: 4.1yrs
  • Walter Reinisch

    Member of Medical & Scientific Advisory Board

    • Tenure: 0.6yrs

Company Information

Algernon Pharmaceuticals Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Algernon Pharmaceuticals Inc.
  • Ticker: AGN
  • Exchange: CNSX
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$4.305m
  • Shares outstanding: 71.75m
  • Website: https://algernonpharmaceuticals.com

Location

  • Algernon Pharmaceuticals Inc.
  • 700 West Pender Street
  • Suite 915
  • Vancouver
  • British Columbia
  • V6C 1G8
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AGNCNSX (Canadian National Stock Exchange)YesCommon SharesCACADFeb 2016
AGWDB (Deutsche Boerse AG)YesCommon SharesDEEURFeb 2016

Biography

Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company was form ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/16 00:37
End of Day Share Price2019/11/15 00:00
Earnings2019/05/31
Annual Earnings2018/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.